We Are Patient Focused and Outcomes Driven

Here at Ardelyx, we are dedicated to improving the lives of patients by developing and commercializing first-in-class targeted therapies that advance patient care. Using our discovery model, Ardelyx scientists have identified new biological mechanisms and pathways that have enabled us to develop a pipeline of drug candidates designed to better manage complications related to kidney and cardiorenal diseases with the goal of improving outcomes for this large population of underserved patients.


Our lead candidate, tenapanor, is a first-in-class, targeted, small molecule therapy under FDA review for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. The company believes that, if approved, tenapanor could become a foundational therapy for all patients on dialysis who suffer from hyperphosphatemia, a condition of elevated levels of phosphate in the blood, completely changing the treatment paradigm and making effective and consistent phosphate control possible.

Our Pipeline

We are also developing earlier-stage candidates that further leverage our discovery capabilities and deep understanding of transport mechanisms, targeting specific pharmacologic pathways. RDX013 is a program focused on developing drug candidates for the treatment of hyperkalemia, a condition resulting from elevated levels of potassium in the blood, and additional pre-clinical projects across other indications are advancing.

Ardelyx is publicly traded on the Nasdaq Global Market under the symbol ARDX. Tapping into the best talent on both coasts and everywhere in between, we maintain dual headquarters in the greater San Francisco and Boston biotech communities.


Our Commitment to Compliance

At Ardelyx, we foster a culture of compliance and hold our employees, contractors, and other representatives acting on our behalf to a high standard of business and professional conduct. Our core values—passionate, fearless, dedicated, inclusive—guide how we treat each other, our customers, and our patients.

Ardelyx Core Values


With integrity and determination, we make a difference for patients.


By challenging convention, we truly innovate.


Working tirelessly together, we are greater than the sum of our parts.


With respect, grace and humor, we are family.

Management Team

Mike Raab

President &
Chief Executive Officer

Robert Blanks, MS RAC

Chief Regulatory Affairs &
Quality Assurance Officer

Elizabeth Grammer, Esq.

Chief Legal &
Administrative Officer

David Rosenbaum, PhD

Chief Development Officer

Jeff Jacobs, PhD

Chief Scientific Officer


Justin Renz

Chief Financial Officer

Susan Rodriguez

Chief Commercial Officer

Laura Williams, MD MPH

Senior Vice President, Global Therapeutic Strategies and Patient Advocacy

Sarah O’Brien

Chief People Officer

Board of Directors

David Mott


Geoffrey A. Block, MD


Mike Raab


Robert Bazemore


Onaiza Cadoret-Manier


Muna Bhanji, R.Ph


William A. Bertrand, Jr., JD


Jan M. Lundberg, PhD


Richard Rodgers


Scientific Advisory Board

Geoffrey A. Block, MD

Kevin J. Martin, MB, BCh, BAO

Glenn M. Chertow, MD, MPH

Sharon M. Moe, MD

Stuart M. Sprague, DO

Derek Forfang

Rory C. Pace, MPH, RD, CSR, FAND

Francesca Tentori, MD, MS

Kam Kalantar-Zadeh, MD, MPH, PhD

Pablo E. Pergola, MD, PhD

Logo Alt

Our Logo

The Ardelyx “A” – Since our founding in 2007, we have been focused on translating our deep understanding of biological mechanisms of ion transport into life-changing medicines. Our stylized “A” visually represents the promise of therapeutics when they interact with specific biological targets. While our logo has evolved over time, we have maintained our unique “A” to recognize our lasting commitment to scientific discovery for the benefit of patients.